ArticleIET systems biology
StackAHTPs: An explainable antihypertensive peptides identifier based on heterogeneous features and stacked learning approach.
Article in IET systems biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AMP-CapsNet: a multi-view feature fusion approach for antimicrobial peptide prediction using capsule networks.Genomics & informatics · 2026Article
- StackAHTPs: An explainable antihypertensive peptides identifier based on heterogeneous features and stacked learning approach.IET systems biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hypertension, often known as high blood pressure, is a major concern to millions of individuals globally. Recent studies have demonstrated the significant efficacy of naturally derived peptides in reducing blood pressure. Hypertension is one of the risks associated with cardiovascular disorders and other health problems. Naturally sourced bioactive peptides possessing antihypertensive properties provide considerable potential as viable substitutes for conventional pharmaceutical medications. Currently, thorough examination of antihypertensive peptide (AHTPs), by using traditional wet-lab methods is highly expensive and labours. Therefore, in-silico approaches especially machine-learning (ML) algorithms are favourable due to saving time and cost in the discovery of AHTPs. In this study, a novel ML-based predictor, called StackAHTP was developed for predicting accurate AHTPs from sequence only. The proposed method, utilise two types of feature descriptors Pseudo-Amino Acid Composition and Dipeptide Composition to encode the local and global hidden information from peptide sequences. Furthermore, the encoded features are serially merged and ranked through SHapley Additive explanations (SHAP) algorithm. Then, the top ranked are fed into three different ensemble classifiers (Bagging, Boosting, and Stacking) for enhancing the prediction performance of the model. The StackAHTPs method achieved superior performance compare to other ML classifiers (AdaBoost, XGBoost and Light Gradient Boosting (LightGBM), Bagging and Boosting) on 10-fold cross validation and independent test. The experimental outcomes demonstrate that our proposed method outperformed the existing methods and achieved an accuracy of 92.25% and F1-score of 89.67% on independent test for predicting AHTPs and non-AHTPs. The authors believe this research will remarkably contribute in predicting large-scale characterisation of AHTPs and accelerate the drug discovery process. At https://github.com/ali-ghulam/StackAHTPs you may find datasets features used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.